<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296698</url>
  </required_header>
  <id_info>
    <org_study_id>A6431112</org_study_id>
    <nct_id>NCT01296698</nct_id>
  </id_info>
  <brief_title>Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week Trial to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers in a Naturalistic Environment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to see if a new nicotine replacement therapy safely helps people to quit
      smoking if it is used the way it would be if it were sold at the pharmacy and used at home.
      Approximately 1500 subjects will be enrolled into the study. The study will require
      participants to use the treatment for 12 weeks and there will be a 14-week follow-up period.
      The study will be conducted in approximately 20 pharmacies across the United States.

      At the first visit to the pharmacy, participants will be asked some questions to see if they
      are eligible to participate. Participants will be asked to sign a consent form if they agree
      to participate. Participants will answer some more questions, and blow into a machine to
      measure their carbon monoxide (CO) levels to make sure they qualify for the trial.
      Participants will be asked to go to a nearby dentist who will look at their mouths.
      Participants will go back to the pharmacy and if they qualify, they will be given a supply of
      their assigned treatment. They will have an equal chance of receiving a treatment that has a
      drug in it or one that has no drug in it. They will be given a diary to keep track of how
      much of the treatment they use.

      Subjects will go to the pharmacy four more times to hand in their diaries and blow into a
      machine that will measure their CO levels. At the last visit, subjects will have their mouths
      examined by a dentist again to have their mouth checked.

      Subjects will receive four telephone calls during the study where they will be asked some
      questions.

      After the 12 week treatment period, subjects will receive two to three more telephone calls,
      where they will be asked to answer some questions. Participants may be asked to come back to
      the pharmacy two more times to blow into the carbon monoxide machine again.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a multi-center, randomized, double blind, placebo-controlled parallel group
      study to measure the efficacy and safety of a new nicotine replacement therapy for smoking
      cessation in a naturalistic environment. Subjects will be randomized in a 2:1 ratio (active
      to placebo). It is anticipated that data from about 450 in the active treatment group at Week
      12 will be required for the safety analysis. In order to obtain that number of subjects,
      approximately 1500 subjects will need to be enrolled into the Use phase of the study, 1000 in
      the active arm and 500 in the placebo arm.

      Based on the directions for use on the Drug Facts label, the study will include six weeks of
      full study drug treatment and then six weeks of progressive tapering drug treatment (Weeks
      1-12). There will be a 14-week post-use follow up period.

      This trial will be conducted in three sequential phases: Enrollment (baseline), Use and
      Post-use Follow-up. The Enrollment Phase will be conducted in approximately 20 pharmacies in
      nine diverse geographical areas in the continental United States. Subjects who qualify to
      participate in the study will be given three units of investigational product, a subject
      diary for tracking investigational product use and a medical problems worksheet to assist in
      the collection of AE information. Subjects will also be given a small hand counter and will
      be encouraged to use it to help keep track of the number of doses they use each day. Subjects
      will also be given a card with contact information for the pharmacy and study nurses. Where
      needed, the subject can also speak with the study physician.

      During the Use Phase, the collection of data related to efficacy will be accomplished during
      four return visits to the pharmacy (at weeks 2, 4, 6 and 12). Self-reported abstinence will
      be verified by carbon monoxide (CO) measurements obtained at each pharmacy visit. Subjects
      will be given a subject use diary at each follow-up and re-supply visit and completed diaries
      will be collected each time the subject returns to the pharmacy. Subjects can return to the
      pharmacy for additional supplies at any time during their participation. Empty units will be
      returned during these visits.

      Safety data will be collected during four telephone interviews, conducted by trained nurse
      interviewers, at weeks 2, 4, 6 and 12. If a subject reports an adverse event during a visit
      (return visit or resupply visit), this information will be immediately forwarded to the nurse
      interviewers for follow-up. Subjects may also initiate a call to the study nurses themselves
      to discuss health problems. All AE information collected will be reviewed by a physician as
      the adverse events are collected. A standardized visual mouth examination will be conducted
      by trained dentists at the enrollment visit and at the Week 12 return visit.

      During the Post-use Follow-up period, self-reported efficacy and safety data will be
      collected during two telephone interviews initiated by trained nurse interviewers (at weeks
      16 and 26). Subjects reporting abstinence since the last visit or abstinence for the prior
      seven days during these two interviews will be asked to return to the pharmacy to verify
      abstinence with an exhaled CO measurement. An additional telephone interview will be
      conducted between Week-12 and Week-16, by trained nurse interviewers, who will administer the
      End of Treatment questions to those subjects who have reported the following product use
      behavior that are inconsistent with the directions on the Drug Facts label: Use of more than
      64 doses in a 24-hour period at least one time or use of more than 4 doses per hour at least
      one time based on the diary or their self report.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to a technical issue (randomization error).
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Continuous Smoking Abstinence</measure>
    <time_frame>through Week 6</time_frame>
    <description>Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Continuous Smoking Abstinence</measure>
    <time_frame>through Week 26</time_frame>
    <description>Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 7-day Point Prevalence Abstinence</measure>
    <time_frame>through Week 26</time_frame>
    <description>Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 1</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 2</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 3</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 4</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 5</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Daily Doses</measure>
    <time_frame>Week 6</time_frame>
    <description>Mean number of daily doses by study week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With High Dosage</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Percentage of participants who used more than 64 doses in any one-day period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With High Usage</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Percentage of participants who used more than four doses in any one-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Desire/Urge to Smoke on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Irritability/Frustration/Anger on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Restlessness on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Difficulty Concentrating on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Anxiety on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Insomnia on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Rating of Increased Appetite on a Categorical Scale</measure>
    <time_frame>within 12 Weeks</time_frame>
    <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score for General Perception of the Product</measure>
    <time_frame>through Week 12</time_frame>
    <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score for Product Effectiveness in Dealing With Cravings</measure>
    <time_frame>through 12 Weeks</time_frame>
    <description>Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score for Speed of Action</measure>
    <time_frame>through 12 Weeks</time_frame>
    <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score for Change in Perception</measure>
    <time_frame>through 12 Weeks</time_frame>
    <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Score for Product Convenience</measure>
    <time_frame>through 12 Weeks</time_frame>
    <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Not marketed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks</description>
    <arm_group_label>Nicotine</arm_group_label>
    <other_name>Not yet marketed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be males or females 18 years of age or older who currently smoke
             cigarettes and are willing to stop smoking

        Exclusion Criteria:

          -  Subjects must not have a recent history of unstable angina, myocardial infarction or
             stroke

          -  They must not have a suspected malignant and/or erosive oral lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Qi, MD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avalon Discount Drugs</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coast Compounding Pharmacy</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wynn's Pharmacy, Inc.</name>
      <address>
        <city>Griffin</city>
        <state>Georgia</state>
        <zip>30224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stark Pharmacy</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>Anoka</city>
        <state>Minnesota</state>
        <zip>55303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>Elk River</city>
        <state>Minnesota</state>
        <zip>55330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodrich Pharmacy</name>
      <address>
        <city>St. Francis</city>
        <state>Minnesota</state>
        <zip>55070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cub Pharmacy #1924</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicap Pharmacy</name>
      <address>
        <city>Clarksdale</city>
        <state>Mississippi</state>
        <zip>38614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liddy's Health Mart</name>
      <address>
        <city>Holly Springs</city>
        <state>Mississippi</state>
        <zip>38635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Countryside Pharmacy</name>
      <address>
        <city>Savannah</city>
        <state>Missouri</state>
        <zip>64485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phil's Pills</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerr Drug</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Prescription Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.B. Bond Pharmacy</name>
      <address>
        <city>Hillsboro</city>
        <state>Texas</state>
        <zip>76645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inwood Pharmacy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Morgan Drug #1</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brick Street Pharmacy</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpelier Pharmacy, Inc.</name>
      <address>
        <city>Montpelier</city>
        <state>Virginia</state>
        <zip>23192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2012</results_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Nicotine</title>
          <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulty Contacting Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Nicotine</title>
          <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="14.0"/>
                    <measurement group_id="B2" value="49.9" spread="11.4"/>
                    <measurement group_id="B3" value="47.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Continuous Smoking Abstinence</title>
        <description>Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6.</description>
        <time_frame>through Week 6</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Continuous Smoking Abstinence</title>
          <description>Number of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking from Week 2 through Week 6.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Continuous Smoking Abstinence</title>
        <description>Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26.</description>
        <time_frame>through Week 26</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Continuous Smoking Abstinence</title>
          <description>Number of participants with carbon monoxide (CO)-verified self report of continuous abstinence from smoking from Week 2 to Weeks 4, 6, 12, 16, and 26.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 7-day Point Prevalence Abstinence</title>
        <description>Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26.</description>
        <time_frame>through Week 26</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 7-day Point Prevalence Abstinence</title>
          <description>Number of participants with carbon monoxide (CO)-verified self-reported 7-day point prevalence abstinence from smoking at Weeks 2, 4, 6, 12, 16, and 26.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 1</time_frame>
        <population>Analysis was limited to data collected from participants at Week 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 1.</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="11.7"/>
                    <measurement group_id="O2" value="14.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 2</time_frame>
        <population>Analysis was limited to data collected from participants at Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 2.</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="11.4"/>
                    <measurement group_id="O2" value="18.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 3</time_frame>
        <population>Analysis was limited to data collected from participants at Week 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 3.</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="9.4"/>
                    <measurement group_id="O2" value="15.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 4</time_frame>
        <population>Analysis was limited to data collected from participants at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 4.</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="10.8"/>
                    <measurement group_id="O2" value="10.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 5</time_frame>
        <population>Analysis was limited to data collected from participants at Week 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 5.</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="11.3"/>
                    <measurement group_id="O2" value="4.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Daily Doses</title>
        <description>Mean number of daily doses by study week.</description>
        <time_frame>Week 6</time_frame>
        <population>Analysis was limited to data collected from participants at Week 6. Analysis of data for the remainder of the study weeks was not possible because the trial terminated prematurely due to a technical issue (randomization error).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Daily Doses</title>
          <description>Mean number of daily doses by study week.</description>
          <population>Analysis was limited to data collected from participants at Week 6. Analysis of data for the remainder of the study weeks was not possible because the trial terminated prematurely due to a technical issue (randomization error).</population>
          <units>Daily Doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With High Dosage</title>
        <description>Percentage of participants who used more than 64 doses in any one-day period.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to data collected from participants who had used study medication at least one day.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With High Dosage</title>
          <description>Percentage of participants who used more than 64 doses in any one-day period.</description>
          <population>Analysis was limited to data collected from participants who had used study medication at least one day.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With High Usage</title>
        <description>Percentage of participants who used more than four doses in any one-hour period.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to data collected from participants who had used study medication at least one day.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With High Usage</title>
          <description>Percentage of participants who used more than four doses in any one-hour period.</description>
          <population>Analysis was limited to data collected from participants who had used study medication at least one day.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Desire/Urge to Smoke on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Desire/Urge to Smoke on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced the Desire/Urge to Smoke on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Irritability/Frustration/Anger on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Irritability/Frustration/Anger on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Irritability/Frustration/Anger on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Restlessness on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Restlessness on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Restlessness on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Difficulty Concentrating on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Difficulty Concentrating on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Difficulty Concentrating on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Anxiety on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Anxiety on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Anxiety on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Dysphoric or Depressed Mood on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Dysphoric or Depressed Mood on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Insomnia on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Insomnia on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Insomnia on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Rating of Increased Appetite on a Categorical Scale</title>
        <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so.</description>
        <time_frame>within 12 Weeks</time_frame>
        <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Rating of Increased Appetite on a Categorical Scale</title>
          <description>Participants are asked if during the last 24 hours they experienced Increased Appetite on a 5-grade categorical scale from Not at all to Extremely so.</description>
          <population>Analysis was limited to participants who used study medication at least once and who completed the questionnaire.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not at all</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very much so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely so</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score for General Perception of the Product</title>
        <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
        <time_frame>through Week 12</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score for General Perception of the Product</title>
          <description>Participants are asked to rate their general perception of the investigational product on a scale of 1-10, where 1=very poor and 10=excellent.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score for Product Effectiveness in Dealing With Cravings</title>
        <description>Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective.</description>
        <time_frame>through 12 Weeks</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score for Product Effectiveness in Dealing With Cravings</title>
          <description>Participants are asked to rate the product in its effectiveness for dealing with cravings, on a scale of 1-5, where 1=not at all effective, and 5=extremely effective.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score for Speed of Action</title>
        <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
        <time_frame>through 12 Weeks</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score for Speed of Action</title>
          <description>Participants are asked to rate the product for speed of action, on a scale of 1-9, where 1=extremely slow and 9=extremely fast.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score for Change in Perception</title>
        <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
        <time_frame>through 12 Weeks</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score for Change in Perception</title>
          <description>Participants are asked to rate how their opinion has changed since the first time they used it, on a score of 1-5, where 1=I like it much less now and 5=I like it much more now.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Score for Product Convenience</title>
        <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
        <time_frame>through 12 Weeks</time_frame>
        <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nicotine</title>
            <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Score for Product Convenience</title>
          <description>Participants are asked to rate how convenient the product is to use, on a scale of 1-5, where 1=not at all convenient and 5=extremely convenient.</description>
          <population>The study was terminated prematurely due to a technical issue (randomization error) and no data are available.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during study and during telephone interview after study termination. Serious adverse events and adverse events categorized as probably or very likely related to study product were followed until they resolved or stabilized.</time_frame>
      <desc>Two subjects who did not receive study medication were excluded from the safety analysis set as defined in the Statistical Analysis Plan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Nicotine</title>
          <description>1 mg Oral NRT, up to 4 times per hour for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gingival Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sensitivity of Teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators agreed not to discuss or publish the details/results of this study.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Summary tabulations are not available for the primary and some secondary outcome measures because the study was terminated early due to a technical issue (randomization error).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joyce Hauze, RPS Sr. Specialist, Clinical Research Operations</name_or_title>
      <organization>Johnson &amp; Johnson Consumer and Personal Products Worldwide</organization>
      <phone>928-277-0715</phone>
      <email>jhauze@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

